NH TherAguix is a French biotech start-up based in Grenoble, created in 2015 after 10 years of preclinical research. NH TherAguix produces and develops its drug candidate AGuIX, with the goal to improve the efficacy of radiotherapy of cancer leading to a better survival and quality of life. The company is pursuing its strategy ambitiously and currently focused on its clinical development in the USA and in Europe, and on the preclinical development of a second-generation drug.
Targeting indications :
Lung cancer, Colorectal cancer, Brain cancer, Head and neck cancers, Gynecological cancers